Utility of the Modified Ottawa Score for Identification of More Preferable Candidates of Extended Anticoagulation therapy in Cancer-associated Isolated Distal Deep Vein Thrombosis: Insight from the ONCO DVT Study

Authors

Wei Xiong

Published

September 1, 2024

Abstract

The ONCO DVT study revealed superiority of 12-month relative to 3-month edoxaban treatment for the thrombotic risk in cancer-associated isolated distal deep vein thrombosis (DVT). However, it is unknown whether the superiority could be common in different modified Ottawa score subgroups.